The computer model of human physiology structures data in a way that enables identification of the key factors associated with the development of skin sensitization. Entelos claims the virtual patient model helps researchers visualize the pathways contributing to skin sensitization and allows hypotheses to be rapidly tested via computer simulation.
Entelos added that the virtual patient is not exclusive to Unilever, and it retains full rights to use the technology independently, including rights for all pharmaceutical applications.
“We are pleased to be able to apply our unique technology and approach to accelerate the search for safe and effective ingredients for consumer and pharmaceutical products,” stated James Karis, president and CEO of Entelos. “The innovative skin sensitization computer model is designed to help its customers develop alternative approaches to assessing the safety of consumer products.”